It seems Nestlé is experiencing some buyer’s remorse two years after throwing down $2.6 billion for Aimmune Therapeutics and its peanut allergy pill Palforzia.
Aimmune Therapeutics to Present Positive Results from Phase 3 POSEIDON Study of PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] in Peanut-Allergic Children Aged 1 to 3 Years
ASHEVILLE, N.C. & BRISBANE, Calif.--(BUSINESS WIRE)--Allergy Partners, the nation’s largest single specialty allergy practice group leading the development and delivery of high-quality health care for patients with asthma and allergic disease, today announced a strategic collaboration with Aimmune Therapeutics, Inc., a Nestlé Health Science company developing pharmaceutical therapies to prevent, manage, and treat food, gastrointestinal, and metabolic-related diseases, to provide Allergy Partners’ patients aged 4 through 17 years with a confirmed diagnosis of peanut allergy with direct access to PALFORZIA, the first and only FDA-approved peanut allergy treatment.
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc., a Nestlé Health Science company developing pharmaceutical therapies to prevent, manage, and treat food, gastrointestinal (GI), and metabolic-related diseases, will present new data on PALFORZIA® [Peanut Allergen (Arachis hypogaea) Power-dnfp] at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress in Prague, Czech Republic on July 1-3, 2022.
A Phase II trial for Aimmune’s drug to treat children and young adults with egg allergies has been terminated.
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc., a Nestlé Health Science company developing pharmaceutical therapies to prevent, manage, and treat food, gastrointestinal (GI), and metabolic-related diseases, today announced the publication of new clinical data from a pooled analysis of three controlled phase 3 (PALISADE, RAMSES, ARTEMIS) and two open-label extension trials (ARC004, ARC011) of PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] in the Journal of Allergy and Clinical Immunology (JACI).
NEW YORK, Nov. 16, 2021 /PRNewswire/ -- The nonprofit Mission: Cure, with the support of Aimmune Therapeutics, Inc., a Nestlé Health Science Company, has launched a new patient online community on the HealthUnlocked network, which will provide valuable support and information to people living with pancreatitis, helping them to live healthier lives. The online community is a much-needed space for patients who are suffering from this debilitating and isolating disease to connect and share their journey with pancreatitis in a supportive environment. Patients can join the community by following this link: https://healthunlocked.com/pancreatitis-support
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc., a Nestlé Health Science company developing and commercializing pharmaceutical therapies to prevent, manage, and treat food and metabolic-related diseases, today presented results from longitudinal analyses evaluating immunological outcomes of long-term daily oral immunotherapy (OIT) with PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] in patients with peanut allergy (PA) for up to 6 years, as well as new data on the utility benefits for Quality of Life (QoL) between pre- and post-OIT health states in children and adolescents with PA who received PALFORZIA and their caregivers in the United Kingdom (U.K.). The data will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) Pediatric Allergy and Asthma Meeting (PAAM) Digital Event, November 12-13, 2021.
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc., a Nestlé Health Science company developing and commercializing pharmaceutical therapies to prevent, manage, and treat food and metabolic-related diseases, today announced it will present new data on the burden of peanut allergy (PA) on patients’ and caregivers’ Quality of Life. In addition, the company will share results from physician surveys on real-world experiences with PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] that explore treatment adoption in clinical practice in the U.S. The data will be presented at the American College of Asthma, Allergy, and Immunology (ACAAI) Annual Scientific Meeting on November 4-8, 2021, in New Orleans.
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc., a Nestlé Health Science company developing and commercializing pharmaceutical therapies to prevent, manage, and treat food and metabolic-related diseases, today announced it will present new data on the burden of peanut allergy (PA) on patients’ and caregivers’ Quality of Life. In addition, the company will share results from physician surveys on real-world experiences with PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] that explore treatment adoption in clinical practice in the U.S. The data will be presented at the American College of Asthma, Allergy, and Immunology (ACAAI) Annual Scientific Meeting on November 4-8, 2021, in New Orleans.